Genome-scale metabolic modeling (GEM) is one of the key approaches to unpack cancer metabolism and for discovery of new drug targets. In this study, we report the Transcriptional Regulated Flux Balance Analysis-CORE (TRFBA-), an algorithm for GEM using key growth-correlated reactions using hepatocellular carcinoma (HCC), an important global health burden, as a case study. We generated a HepG2 cell-specific GEM by integrating this cell line transcriptomic data with a generic human metabolic model to forecast potential drug targets for HCC. A total of 108 essential genes for growth were predicted by the TRFBA-CORE. These genes were enriched for metabolic pathways involved in cholesterol, sterol, and steroid biosynthesis. Furthermore, we silenced a predicted essential gene, 11-beta dehydrogenase hydroxysteroid type 2 (HSD11B2), in HepG2 cells resulting in a reduction in cell viability. To further identify novel potential drug targets in HCC, we examined the effect of nine drugs targeting the essential genes, and observed that most drugs inhibited the growth of HepG2 cells. Some of these drugs in this model performed better than Sorafenib, the first-line therapeutic against HCC. A HepG2 cell-specific GEM highlights sterol metabolism to be essential for cell growth. HSD11B2 downregulation results in lower cell growth. Most of the compounds, selected by drug repurposing approach, show a significant inhibitory effect on cell growth in a wide range of concentrations. These findings offer new molecular leads for drug discovery for hepatic cancer while also illustrating the importance of GEM and drug repurposing in cancer therapeutics innovation.
Get full access to this article
View all access options for this article.
References
1.
AgrenR, BordelS, MardinogluA, et al.Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput Biol, 2012; 8(5):e1002518; doi: 10.1371/journal.pcbi.1002518
2.
AgrenR, LiuL, ShoaieS, et al.The RAVEN toolbox and its use for generating a genome-scale metabolic model for penicillium chrysogenum. PLoS Comput Biol, 2013; 9(3):e1002980; doi: 10.1371/journal.pcbi.1002980
3.
AgrenR, MardinogluA, AsplundA, et al. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol Syst Biol, 2014; 10:1–13.
4.
AnnaM, MeloneB, ValentinoA, et al.The carnitine system and cancer metabolic plasticity. Cell Death Dis, 2018; 9:228; doi: 10.1038/s41419-018-0313-7
5.
AshtonTM, FokasE, Kunz-schughartLA, et al.The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nat Commun, 2016; 7:12308; doi: 10.1038/ncomms12308
6.
AshworthA, LordCJ. Synthetic lethal therapies for cancer: What's next after PARP inhibitors?. Nat Rev Clin Oncol, 2018; 15(9):564–576; doi: 10.1038/s41571-018-0055-6
7.
AuslanderN, CunninghamCE, ToosiBM, et al.An integrated computational and experimental study uncovers FUT 9 as a metabolic driver of colorectal cancer. Mol Syst Biol, 2017; 13(12):956; doi: 10.15252/msb.20177739
8.
AzherS, AzamiO, AmatoC, et al.The non-conventional effects of glucocorticoids in cancer. J Cell Physiol, 2016; 231(11):2368–2373; doi: 10.1002/jcp.25408
9.
BarfeldSJ, FazliL, PerssonM, et al. Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. Oncotarget, 2015; 6(14):12587–12602.
10.
BeckerSA, PalssonBO. Context-specific metabolic networks are consistent with experiments. PLoS Comput Biol, 2008; 4(5):e1000082; doi: 10.1371/journal.pcbi.1000082
11.
BertoliniF, SukhatmeVP, BoucheG. Drug repurposing in oncology—Patient and health systems opportunities. Nat Rev Clin Oncol, 2015; 12(12):732–742; doi: 10.1038/nrclinonc.2015.169
12.
BiancoC, JamialahmadiO, PelusiS, et al.Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol, 2021; 74(4):775–782; doi: 10.1016/j.jhep.2020.11.024
13.
BidkhoriG, BenfeitasR, ElmasE, et al.Metabolic network-based identification and prioritization of anticancer targets based on expression data in hepatocellular carcinoma. Front Physiol, 2018; 9:916; doi: 10.3389/fphys.2018.00916
14.
BonatePL, ArthaudL, CantrellWR, et al.Discovery and development of clofarabine: A nucleoside analogue for treating cancer. Nat Rev Drug Discov, 2006; 5(10):855–863; doi: 10.1038/nrd2055
15.
BordbarA, MonkJM, KingZA, et al.Constraint-based models predict metabolic and associated cellular functions. Nat Rev Genet, 2014; 15(2):107–120; doi: 10.1038/nrg3643
16.
BrienEJO, MonkJM, PalssonBO. Using genome-scale models to predict biological capabilities. Cell, 2015; 161(5):971–987; doi: 10.1016/j.cell.2015.05.019
17.
ChenS, ChouC, ChangC, et al. HMGCS2 enhances invasion and metastasis via direct interaction with PPARα to activate src signaling in colorectal cancer and oral cancer. Oncotarget, 2017; 8(14):22460–22476.
18.
ChuaM, BernsteinLR, LiR, et al. Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res, 2006; 1744:1739–1743.
19.
De MatteisS, RagusaA, MarisiG, et al.Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities. Egea J Oxid Med Cell Longev, 2018; 2018:7512159; doi: 10.1155/2018/7512159
20.
DuarteNC, BeckerSA, JamshidiN, et al.Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci U S A, 2007; 104(6):1777–1782; doi: 10.1073/pnas.0610772104
21.
EdgarR, DomrachevM, LashAE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res, 2002; 30(1):207–210.
22.
EfferthT, GebhartE, RossDD, et al.Identification of gene expression profiles predicting tumor cell response to L-alanosine. Biochem Pharmacol, 2003; 66(4):613–621; doi: 10.1016/S0006-2952(03)00341-1
23.
FiorilloM, LambR, TanowitzHB, et al. Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget, 2016; 7(23):34084–34099.
24.
FolgerO, JerbyL, FrezzaC, et al.Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol, 2011; 7:501; doi: 10.1038/msb.2011.35
25.
FouladihaH, MarashiS-A, ShokrgozarMA. Reconstruction and validation of a constraint-based metabolic network model for bone marrow-derived mesenchymal stem cells. Cell Prolif, 2015; 48(4):475–485; doi: 10.1111/cpr.12197
26.
FurutaE, OkudaH, KobayashiA, et al.Metabolic genes in cancer: Their roles in tumor progression and clinical implications. Biochim Biophys Acta Rev Cancer, 2010; 1805(2):141–152; doi: 10.1016/j.bbcan.2010.01.005
27.
GhaffariP, MardinogluA, AsplundA, et al.Identifying anti-growth factors for human cancer cell lines through genome-scale metabolic modeling. Sci Rep, 2015; 5:1–10; doi: 10.1038/srep08183
28.
GoodingJR, JensenMV, DaiX, et al.Adenylosuccinate is an insulin secretagogue derived from glucose-induced purine metabolism article adenylosuccinate is an insulin secretagogue derived from glucose-induced purine metabolism. Cell Rep, 2015; 13(1):157–167; doi: 10.1016/j.celrep.2015.08.072
29.
GuptaSC, SungB, PrasadS, et al.Cancer drug discovery by repurposing: Teaching new tricks to old dogs. Trends Pharmacol Sci, 2013; 34(9):508–517; doi: 10.1016/j.tips.2013.06.005
30.
HeY, GaoM, TangH, et al.Metabolic intermediates in tumorigenesis and progression. Int J Biol Sci, 2019; 15:1187–1199; doi: 10.7150/ijbs.33496
31.
HollandPM, AbramsonRD, WatsonR, et al.Detection of specific polymerase chain reaction product by utilizing the 5′–3′ exonuclease activity of thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A, 1991; 88(16):7276–7280; doi: 10.1073/pnas.88.16.7276
32.
HydukeDR, LewisNE, PalssonBØ. Analysis of omics data with genome-scale models of metabolism. Mol Bio Syst, 2013; 9(2):167–174; doi: 10.1039/C2MB25453K
33.
IoannouGN.The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metab, 2016; 27(2):84–95; doi: 10.1016/j.tem.2015.11.008
34.
JainM, NilssonR, SharmaS, et al.Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science, 2012; 336(6084):1040–1044; doi: 10.1126/science.1218595
35.
JamialahmadiO, Hashemi-NajafabadiS, MotamedianE, et al. A benchmark-driven approach to reconstruct metabolic networks for studying cancer metabolism. PLoS Comput Biol, 2019; 15(4); doi: 10.1371/journal.pcbi.1006936
36.
JerbyL, RuppinE. Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling. Clin Cancer Res, 2012; 18(20):5572–5585; doi: 10.1158/1078-0432.CCR-12-1856
37.
JerbyL, ShlomiT, RuppinE. Computational reconstruction of tissue-specific metabolic models: Application to human liver metabolism. Mol Syst Biol, 2010; 6(401):1–9; doi: 10.1038/msb.2010.56
38.
KatamuraY, AikataH, HashimotoY, et al.Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma. Hepatol Res, 2010; 40(12):1195–1203; doi: 10.1111/j.1872-034X.2010.00729.x
39.
KhazaeiT, McguiganA, MahadevanR. Ensemble modeling of cancer metabolism. Front Physiol, 2012; 3(May):1–14; doi: 10.3389/fphys.2012.00135
40.
KuleshovMV, JonesMR, RouillardAD, et al.Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res, 2016; 44(May):90–97; doi: 10.1093/nar/gkw377
41.
LewisNE, Abdel-haleemAM. The evolution of genome-scale models of cancer metabolism. Front Physiol, 2013;4(September):1–7:237; doi: 10.3389/fphys.2013.00237
42.
LiL, NgSR, ColónCI, et al.Identification of DHODH as a therapeutic target in small cell lung cancer. Sci Transl Med, 2019; 11:eaaw7852; doi: 10.1126/scitranslmed.aaw7852
43.
LiT, FanJ, WangB, et al.TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res, 2017; 77(21):108–111; doi: 10.1158/0008-5472.CAN-17-0307
44.
LiangJQ, TeohN, XuL, et al.Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. Nat Commun, 2018; 9:4490; doi: 10.1038/s41467-018-06931-6
45.
LiuP, TsaiK, HsuC, et al.Drug repurposing screening identifies tioconazole as an ATG4 inhibitor that suppresses autophagy and sensitizes cancer cells to chemotherapy. Theranostics, 2018; 8(3):830–845; doi: 10.7150/thno.22012
46.
LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods, 2001; 25(4):402–408; doi: 10.1006/meth.2001.1262
47.
LoombaR, FriedmanSL, ShulmanGI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 2021; 184(10):2537–2564; doi: 10.1016/j.cell.2021.04.015
48.
LuL, ZhaoG, Luu-TheV, et al.Expression of 11β-hydroxysteroid dehydrogenase type 1 in breast cancer and adjacent non-malignant tissue. An immunocytochemical study. Pathol Oncol Res, 2011; 17(3):627–632; doi: 10.1007/s12253-011-9361-3
49.
MaR, ZhangW, TangK, et al.Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma. Nat Commun, 2013; 4:2508; doi: 10.1038/ncomms3508
50.
MarchiE, MangoneM, ZulloK, et al.Pralatrexate pharmacology and clinical development. Clin Cancer Res, 2013; 19:6657–6662; doi: 10.1158/1078-0432.CCR-12-2251
51.
MardinogluA, AgrenR, KampfC, et al.Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat Commun, 2014; 5(May 2013):1–11; doi: 10.1038/ncomms4083
52.
MayerRJ, Van CustemE, FalconeA, et al.Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med, 2015; 372:1909–1919; doi: 10.1056/NEJMoa1414325
53.
McfarlandJM, HoZV, KugenerG, et al.Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun, 2018; 9:1–13; doi: 10.1038/s41467-018-06916-5
54.
MotamedianE, MohammadiM, ShojaosadatiSA, et al.TRFBA: An algorithm to integrate genome-scale metabolic and transcriptional regulatory networks with incorporation of expression data. Bioinformatics, 2017; 33:1057–1063; doi: 10.1093/bioinformatics/btw772
55.
MukhopadhyayB, BjoE, AsplundA, et al.Stratification of hepatocellular carcinoma patients based on acetate utilization. Cell Rep, 2015; 13:2014–2026; doi: 10.1016/j.celrep.2015.10.045
56.
MullenPJ, YuR, LongoJ, et al.The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer, 2016; 16(11):718–731; doi: 10.1038/nrc.2016.76
NozakiA, MorimotoM, KondoM, et al.Hydroxyurea as an inhibitor of hepatitis C virus RNA replication. Arch Virol, 2010; 155(4):601–605; doi: 10.1007/s00705-010-0624-1
59.
OpdamS, RichelleA, KellmanB, et al. A systematic evaluation of methods for tailoring genome-scale metabolic models. Cell Syst, 2017; 4(3):318–329.e6; doi: 10.1016/j.cels.2017.01.010
60.
PachecoMP, JohnE, KaomaT, et al.Integrated metabolic modelling reveals cell-type specific epigenetic control points of the macrophage metabolic network. BMC Genomics, 2015; 16:1–24; doi: 10.1186/s12864-015-1984-4
61.
PelizzaroF, SammarcoA, DadduzioV, et al.Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Dig Liver Dis, 2019; 51(12):1713–1719; doi: 10.1016/j.dld.2019.06.015
62.
RaimondiMV, RandazzoO, Franca MLa, et al.DHFR inhibitors: Reading the past for discovering novel anticancer agents. Molecules, 2019; 24:1–19; doi: 10.3390/molecules24061140
SalehabadiE, MotamedianE, ShojaosadatiSA. Reconstruction of a generic genome-scale metabolic network for chicken: Investigating network connectivity and finding potential biomarkers. PLoS One, 2022; 17(3):1–15; doi: 10.1371/journal.pone.0254270
69.
SchultzA, QutubAA. Reconstruction of tissue-specific metabolic networks using CORDA. PLoS Comput Biol, 2016; 12:1–33; doi: 10.1371/journal.pcbi.1004808
70.
SerovaM, BiecheI, SablinM, et al.Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. Br J Cancer, 2011; 104:272–280; doi: 10.1038/sj.bjc.6606063
71.
ShlomiT, CabiliMN, HerrgårdMJ, et al.Network-based prediction of human tissue-specific metabolism. Nat Biotechnol, 2008; 26(9):1003–1010; doi: 10.1038/nbt.1487
72.
SwainstonN, SmallboneK, HefziH, et al. Recon 2.2: From reconstruction to model of human metabolism. Metabolomics, 2016; 12(7);109; doi: 10.1007/s11306-016-1051-4
73.
SykesDB.The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia in acute myeloid leukemia. Expert Opin Ther Targets, 2018; 22(11):893–898; doi: 10.1080/14728222.2018.1536748
74.
TangZ, LiC, KangB, et al.GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 2017; 45(April):98–102; doi: 10.1093/nar/gkx247
75.
TsengY-Y, BoehmJS. From cell lines to living biosensors: New opportunities to prioritize cancer dependencies using ex vivo tumor cultures. Curr Opin Genet Dev, 2019; 54:33–40; doi: 10.1016/j.gde.2019.02.007
76.
TsunedomiR, IizukaN, HamamotoY, et al.Patterns of expression of cytochrome p450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol, 2005; 27(3):661–667; doi: 10.3892/ijo.27.3.661
77.
ValentiL, PedicaF, ColomboM. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Dig Liver Dis, 2021; doi: 10.1016/j.dld.2021.06.023
78.
VitaleA, TrevisaniF, FarinatiF, et al.Treatment of hepatocellular carcinoma in the precision medicine era: From treatment stage migration to therapeutic hierarchy. Hepatology, 2020; 72(6):2206–2218; doi: 10.1002/hep.31187
79.
VlassisN, PachecoMP, SauterT. Fast reconstruction of compact context-specific metabolic network models. PLoS Comput Biol, 2014; 10(1):e1003424; doi: 10.1371/journal.pcbi.1003424
80.
WadaA, FukuiK, SawaiY, et al.Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma. J Hepatol, 2006; 44:142–150; doi: 10.1016/j.jhep.2005.09.022
81.
WangY, EddyJA, PriceND. Reconstruction of genome-scale metabolic models for 126 human tissues using MCADRE. BMC Syst Biol, 2012; 6:153.
82.
WishartDS, FeunangYD, GuoAC, et al.DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res, 2018; 46(November 2017):1074–1082; doi: 10.1093/nar/gkx1037
83.
XiangM, KimH, HoVT, et al.Gene expression—Based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood, 2016; 128(14):1845–1853; doi: 10.1182/blood-2015-07-660506
84.
YizhakK, ChanetonB, GottliebE, et al.Modeling cancer metabolism on a genome scale. Mol Syst Biol, 2015; 11(6):1–17; doi: 10.15252/msb.20145307
85.
YizhakK, GaudeE, Dévédec SLe, et al.Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer. Elife, 2014; 3:1–23; doi: 10.7554/eLife.03641
86.
ZhaoH, ZhangY, SunJ, et al. Raltitrexed inhibits HepG2 cell proliferation via G0/G1 cell cycle arrest. Oncol Res, 2021; 23:237–248.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
